← Back to Search


YL-13027 for Solid Tumors

MD Anderson Cancer Center, Houston, TX
YL-13027Phase 1RecruitingLed by Trisha Wi Draper, Ph DResearch Sponsored by Shanghai YingLi Pharmaceutical Co. Ltd.

Study Summary

This trial is testing a new drug, YL-13027, to see if it is safe and effective in patients with advanced solid tumors. The first part of the trial (phase Ia) is to determine the best dose of the drug (RP2D) by giving it to a small group of patients. The second part of the trial (phase II) is to expand the study to a larger group of patients to see if the drug has any preliminary anti-tumor activity.

Eligible Conditions
  • Solid Tumors

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~throughout the study for approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout the study for approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency, duration and severity of Adverse Events and Serious Adverse Events
Secondary outcome measures
Clinical Benefit Rate
Duration of Stable Disease
+3 more
Other outcome measures
Plasma tumor antigens

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: YL-13027Experimental Treatment1 Intervention
YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties Chemical Name: 6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg. Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature. Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature.

Find a Location

Who is running the clinical trial?

Shanghai YingLi Pharmaceutical Co. Ltd.Lead Sponsor
19 Previous Clinical Trials
1,484 Total Patients Enrolled
Yingli Pharma US, IncUNKNOWN
1 Previous Clinical Trials
55 Total Patients Enrolled
Trisha Wi Draper, Ph DPrincipal InvestigatorUniversity of Cincinnati Cincinnati, OH 45267-0562

Media Library

YL-13027 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05228600 — Phase 1
Solid Tumors Research Study Groups: YL-13027
Solid Tumors Clinical Trial 2023: YL-13027 Highlights & Side Effects. Trial Name: NCT05228600 — Phase 1
YL-13027 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05228600 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the maximum amount of participants that can take part in this research?

"Affirmative. According to clinicaltrials.gov, this study is actively looking for patients - it was first published on May 17th 2022 and most recently edited on the 16th of the same month. 54 people are needed across a single site in order to complete the trial."

Answered by AI

What potential risks come with the use of YL-13027?

"Given the dearth of data on YL-13027's safety and efficacy, we at Power have rated this experimental medication a 1."

Answered by AI

Is enrollment available for this experimental treatment?

"Yes, the information posted on clinicaltrials.gov implies that this trial is still open to applicants. Initially listed on May 17th 2022 and updated most recently on the 16th of May, it requires 54 patients from a single medical centre."

Answered by AI
~22 spots leftby Nov 2024